Latest Articles
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer - Oncology Learning Network
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer Oncology Learning Network
Published: March 21, 2024, 7 a.m.
Before My Mom's Diagnosis, I Knew Nothing About Endometrial Cancer, Here’s What I Learned - Essence
Before My Mom's Diagnosis, I Knew Nothing About Endometrial Cancer, Here’s What I Learned Essence
Published: March 20, 2024, 7 a.m.
Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer - Oncology News Central
Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer Oncology News Central
Published: March 20, 2024, 7 a.m.
Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer - Medpage Today
Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer Medpage Today
Published: March 19, 2024, 7 a.m.
Studying Endometrial Cancer in Black Women - news.med.miami.edu
Studying Endometrial Cancer in Black Women news.med.miami.edu
Published: March 18, 2024, 7 a.m.
Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer - OncLive
Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer OncLive
Published: March 18, 2024, 7 a.m.
GSK Builds Case for Broader Jemperli Label in Endometrial Cancer with Phase III Data - BioSpace
GSK Builds Case for Broader Jemperli Label in Endometrial Cancer with Phase III Data BioSpace
Published: March 18, 2024, 7 a.m.
AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain - FiercePharma
AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain FiercePharma
Published: March 18, 2024, 7 a.m.
“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer - Oncology News Central
“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer Oncology News Central
Published: March 17, 2024, 7 a.m.
RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer - EurekAlert
RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer EurekAlert
Published: March 16, 2024, 7 a.m.
Link copied to clipboard!